3/19
03:53 pm
trvi
Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its price target lowered by JonesTrading from $25.00 to $24.00. They now have a "buy" rating on the stock.
3/18
06:48 pm
trvi
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Trevi Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
3/18
11:48 am
trvi
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its price target lowered by Morgan Stanley from $19.00 to $18.00. They now have an "overweight" rating on the stock.
3/18
08:40 am
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Medium
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
3/18
08:03 am
trvi
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.
Medium
Report
Trevi Therapeutics (TRVI) had its price target raised by Needham & Company LLC from $22.00 to $24.00. They now have a "buy" rating on the stock.
3/17
11:02 pm
trvi
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Inc (TRVI) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
3/17
04:43 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/17
04:05 pm
trvi
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
3/15
08:05 pm
trvi
A Look At Trevi Therapeutics (TRVI) Valuation After FDA Green Light For Phase 3 Trials [Yahoo! Finance]
Low
Report
A Look At Trevi Therapeutics (TRVI) Valuation After FDA Green Light For Phase 3 Trials [Yahoo! Finance]
3/11
01:18 pm
trvi
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control [Seeking Alpha]
Low
Report
Trevi Therapeutics: Navigating The 'Catch-22' Of Opioid-Based Cough Control [Seeking Alpha]
3/10
04:30 pm
trvi
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026 [Yahoo! Finance]
3/10
04:05 pm
trvi
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
Low
Report
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
3/9
04:42 pm
trvi
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March [Yahoo! Finance]
Low
Report
Up Over 50%: 3 Stocks on the Verge of a Massive Breakout in March [Yahoo! Finance]
3/9
04:05 pm
trvi
Trevi Therapeutics (TRVI) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
Low
Report
Trevi Therapeutics (TRVI) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..
3/9
03:26 pm
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
3/9
12:42 pm
trvi
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics (TRVI) had its "buy" rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
3/9
07:58 am
trvi
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough [Yahoo! Finance]
3/9
07:30 am
trvi
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
High
Report
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
3/2
07:42 am
trvi
Trevi Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Conferences [Yahoo! Finance]
3/2
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming March Conferences
Medium
Report
Trevi Therapeutics to Participate in Upcoming March Conferences
2/28
08:32 pm
trvi
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio [Yahoo! Finance]
Medium
Report
Assessing Trevi Therapeutics (TRVI) Valuation After Strong Long Term Returns And A Rich Price To Book Ratio [Yahoo! Finance]
2/17
07:55 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
2/17
07:30 am
trvi
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Low
Report
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
1/22
12:30 pm
trvi
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
Low
Report
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
1/11
07:40 pm
trvi
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]
Low
Report
Is Trevi Therapeutics (TRVI) Building a Multi-Indication Moat With Its Nalbuphine ER Cough Strategy? [Yahoo! Finance]